Dopamine receptor agonists and antagonists enhance ATP-activated currents

Kazuhide Inoue, Ken Nakazawa, Tomokazu Watano, Mica Ohara-Imaizumi, Kannosuke Fujimori, Akira Takanaka

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The effects of dopamine and related compounds on ATP-activated channels were investigated in pheochromocytoma PC12 cells. Dopamine (10 μM) enhanced an inward current activated by 100 μM ATP. A similar enhancement of the ATP-activated current was observed with apomorphine (10 μM), a non-selective dopamine receptor agonist, with (+)-SKF-38393 (10 μM), a selective dopamine D1 receptor agonist, and with (-)-quinpirole (10 μM), a selective dopamine D2 receptor agonist. Moreover, (+)-SCH-23390 (30 μM), a dopamine D1 receptor antagonist, and (-)-sulpiride (30 μM), a dopamine D2 receptor antagonist, also enhanced the ATP-activated current. The results suggest that ATP-activated channels are modulated by dopaminergic mechanisms, and that this modulation cannot be attributed to any single class of dopamine receptors.

Original languageEnglish
Pages (from-to)321-324
Number of pages4
JournalEuropean Journal of Pharmacology
Volume215
Issue number2-3
DOIs
Publication statusPublished - May 14 1992
Externally publishedYes

Fingerprint

Dopamine Antagonists
Dopamine Agonists
Adenosine Triphosphate
Dopamine D1 Receptors
Dopamine
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine
Quinpirole
Sulpiride
Dopamine D2 Receptors
Apomorphine
PC12 Cells
Dopamine Receptors
Pheochromocytoma

All Science Journal Classification (ASJC) codes

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Inoue, K., Nakazawa, K., Watano, T., Ohara-Imaizumi, M., Fujimori, K., & Takanaka, A. (1992). Dopamine receptor agonists and antagonists enhance ATP-activated currents. European Journal of Pharmacology, 215(2-3), 321-324. https://doi.org/10.1016/0014-2999(92)90049-A

Dopamine receptor agonists and antagonists enhance ATP-activated currents. / Inoue, Kazuhide; Nakazawa, Ken; Watano, Tomokazu; Ohara-Imaizumi, Mica; Fujimori, Kannosuke; Takanaka, Akira.

In: European Journal of Pharmacology, Vol. 215, No. 2-3, 14.05.1992, p. 321-324.

Research output: Contribution to journalArticle

Inoue, K, Nakazawa, K, Watano, T, Ohara-Imaizumi, M, Fujimori, K & Takanaka, A 1992, 'Dopamine receptor agonists and antagonists enhance ATP-activated currents', European Journal of Pharmacology, vol. 215, no. 2-3, pp. 321-324. https://doi.org/10.1016/0014-2999(92)90049-A
Inoue, Kazuhide ; Nakazawa, Ken ; Watano, Tomokazu ; Ohara-Imaizumi, Mica ; Fujimori, Kannosuke ; Takanaka, Akira. / Dopamine receptor agonists and antagonists enhance ATP-activated currents. In: European Journal of Pharmacology. 1992 ; Vol. 215, No. 2-3. pp. 321-324.
@article{533de7d62d54413ead6bff7d40e5d5e5,
title = "Dopamine receptor agonists and antagonists enhance ATP-activated currents",
abstract = "The effects of dopamine and related compounds on ATP-activated channels were investigated in pheochromocytoma PC12 cells. Dopamine (10 μM) enhanced an inward current activated by 100 μM ATP. A similar enhancement of the ATP-activated current was observed with apomorphine (10 μM), a non-selective dopamine receptor agonist, with (+)-SKF-38393 (10 μM), a selective dopamine D1 receptor agonist, and with (-)-quinpirole (10 μM), a selective dopamine D2 receptor agonist. Moreover, (+)-SCH-23390 (30 μM), a dopamine D1 receptor antagonist, and (-)-sulpiride (30 μM), a dopamine D2 receptor antagonist, also enhanced the ATP-activated current. The results suggest that ATP-activated channels are modulated by dopaminergic mechanisms, and that this modulation cannot be attributed to any single class of dopamine receptors.",
author = "Kazuhide Inoue and Ken Nakazawa and Tomokazu Watano and Mica Ohara-Imaizumi and Kannosuke Fujimori and Akira Takanaka",
year = "1992",
month = "5",
day = "14",
doi = "10.1016/0014-2999(92)90049-A",
language = "English",
volume = "215",
pages = "321--324",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "2-3",

}

TY - JOUR

T1 - Dopamine receptor agonists and antagonists enhance ATP-activated currents

AU - Inoue, Kazuhide

AU - Nakazawa, Ken

AU - Watano, Tomokazu

AU - Ohara-Imaizumi, Mica

AU - Fujimori, Kannosuke

AU - Takanaka, Akira

PY - 1992/5/14

Y1 - 1992/5/14

N2 - The effects of dopamine and related compounds on ATP-activated channels were investigated in pheochromocytoma PC12 cells. Dopamine (10 μM) enhanced an inward current activated by 100 μM ATP. A similar enhancement of the ATP-activated current was observed with apomorphine (10 μM), a non-selective dopamine receptor agonist, with (+)-SKF-38393 (10 μM), a selective dopamine D1 receptor agonist, and with (-)-quinpirole (10 μM), a selective dopamine D2 receptor agonist. Moreover, (+)-SCH-23390 (30 μM), a dopamine D1 receptor antagonist, and (-)-sulpiride (30 μM), a dopamine D2 receptor antagonist, also enhanced the ATP-activated current. The results suggest that ATP-activated channels are modulated by dopaminergic mechanisms, and that this modulation cannot be attributed to any single class of dopamine receptors.

AB - The effects of dopamine and related compounds on ATP-activated channels were investigated in pheochromocytoma PC12 cells. Dopamine (10 μM) enhanced an inward current activated by 100 μM ATP. A similar enhancement of the ATP-activated current was observed with apomorphine (10 μM), a non-selective dopamine receptor agonist, with (+)-SKF-38393 (10 μM), a selective dopamine D1 receptor agonist, and with (-)-quinpirole (10 μM), a selective dopamine D2 receptor agonist. Moreover, (+)-SCH-23390 (30 μM), a dopamine D1 receptor antagonist, and (-)-sulpiride (30 μM), a dopamine D2 receptor antagonist, also enhanced the ATP-activated current. The results suggest that ATP-activated channels are modulated by dopaminergic mechanisms, and that this modulation cannot be attributed to any single class of dopamine receptors.

UR - http://www.scopus.com/inward/record.url?scp=0026563028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026563028&partnerID=8YFLogxK

U2 - 10.1016/0014-2999(92)90049-A

DO - 10.1016/0014-2999(92)90049-A

M3 - Article

C2 - 1383001

AN - SCOPUS:0026563028

VL - 215

SP - 321

EP - 324

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 2-3

ER -